by Marisa Wexler, MS | Jan 5, 2026 | Myeloma News
A Phase 3 clinical trial testing the experimental cancer vaccine galinpepimut-S (GPS) in people with acute myeloid leukemia (AML), a type of blood cancer, is nearing its end, according to an update from the therapy’s developer, Sellas Life Sciences. The Phase 3 trial,...
by MM360 Staff | Jan 4, 2026 | Publications
Br J Haematol. 2026 Jan 2. doi: 10.1111/bjh.70323. Online ahead of print. ABSTRACT High-dose melphalan followed by autologous stem cell transplantation (ASCT) is the standard of care for eligible patients with newly diagnosed multiple myeloma (NDMM). A substantial...
by MM360 Staff | Jan 3, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Jan 2, 2026 | Myeloma News
A new Phase 3 clinical trial has officially begun dosing patients to see if an experimental oral therapy can prevent the recurrence of pancreatic cancer following surgery. The study, known as RASolute 304 (NCT07252232), is testing daraxonrasib, a targeted therapy...
by MM360 Staff | Jan 2, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
